End-of-day quote
Other stock markets
|
||
- USD | - |
05:18pm | Pfizer, Genmab Say FDA Approves Tivak to Treat Cervical Cancer | MT |
03:27pm | A flurry of corporate results ahead of the Fed's rate decision |
Sales 2024 * | 59.96B 4,788B | Sales 2025 * | 62.57B 4,997B | Capitalization | 145B 11,596B |
---|---|---|---|---|---|
Net income 2024 * | 6.75B 539B | Net income 2025 * | 9.29B 742B | EV / Sales 2024 * | 3.21 x |
Net Debt 2024 * | 47.04B 3,757B | Net Debt 2025 * | 41.91B 3,347B | EV / Sales 2025 * | 2.99 x |
P/E ratio 2024 * |
18.8
x | P/E ratio 2025 * |
13.7
x | Employees | - |
Yield 2024 * |
6.61% | Yield 2025 * |
6.78% | Free-Float | 59.09% |
Latest transcript on Pfizer Inc
Managers | Title | Age | Since |
---|---|---|---|
Albert Bourla
CEO | Chief Executive Officer | 62 | 31/12/92 |
David Denton
DFI | Director of Finance/CFO | 59 | 01/05/22 |
Jeff Settleman
CTO | Chief Tech/Sci/R&D Officer | - | 30/06/19 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 66 | 31/03/20 | |
Ronald Blaylock
BRD | Director/Board Member | 64 | 22/02/17 |
Shantanu Narayen
BRD | Director/Board Member | 60 | 26/09/13 |
1st Jan change | Capi. | |
---|---|---|
+33.01% | 664B | |
+29.29% | 567B | |
-7.12% | 354B | |
+19.17% | 330B | |
+4.36% | 286B | |
+13.30% | 234B | |
+5.15% | 199B | |
-9.73% | 196B | |
-4.91% | 148B |